First Time Loading...
G

Glenmark Life Sciences Ltd
NSE:GLS

Watchlist Manager
Glenmark Life Sciences Ltd
NSE:GLS
Watchlist
Price: 830.05 INR 1.07% Market Closed
Updated: May 16, 2024

Gross Margin
Glenmark Life Sciences Ltd

56.1%
Current
53%
Average
49%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
56.1%
=
Gross Profit
12.8B
/
Revenue
22.8B

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
IN
Glenmark Life Sciences Ltd
NSE:GLS
101.2B INR
56%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-3%
US
Eli Lilly and Co
NYSE:LLY
748B USD
80%
DK
Novo Nordisk A/S
CSE:NOVO B
4.1T DKK
85%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
56%
US
Johnson & Johnson
NYSE:JNJ
367.4B USD
70%
US
Merck & Co Inc
NYSE:MRK
333.6B USD
75%
UK
AstraZeneca PLC
LSE:AZN
187.7B GBP
82%
CH
Roche Holding AG
SIX:ROG
188.5B CHF
73%
CH
Novartis AG
SIX:NOVN
181.5B CHF
74%
US
Pfizer Inc
NYSE:PFE
162.7B USD
70%
G
Glenmark Life Sciences Ltd
NSE:GLS
Country IN
Market Cap 101.2B INR
Gross Margin
56%
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Country JP
Market Cap 776 550.9T JPY
Gross Margin
-3%
Eli Lilly and Co
NYSE:LLY
Country US
Market Cap 748B USD
Gross Margin
80%
Novo Nordisk A/S
CSE:NOVO B
Country DK
Market Cap 4.1T DKK
Gross Margin
85%
Dechra Pharmaceuticals PLC
LSE:DPH
Country UK
Market Cap 440.4B GBP
Gross Margin
56%
Johnson & Johnson
NYSE:JNJ
Country US
Market Cap 367.4B USD
Gross Margin
70%
Merck & Co Inc
NYSE:MRK
Country US
Market Cap 333.6B USD
Gross Margin
75%
AstraZeneca PLC
LSE:AZN
Country UK
Market Cap 187.7B GBP
Gross Margin
82%
Roche Holding AG
SIX:ROG
Country CH
Market Cap 188.5B CHF
Gross Margin
73%
Novartis AG
SIX:NOVN
Country CH
Market Cap 181.5B CHF
Gross Margin
74%
Pfizer Inc
NYSE:PFE
Country US
Market Cap 162.7B USD
Gross Margin
70%

Profitability Report

View the profitability report to see the full profitability analysis for Glenmark Life Sciences Ltd.

Full Profitability Report

See Also

Summary
GLS intrinsic value, competitors valuation, and company profile.
DCF Valuation
GLS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
GLS stock valuation using valuation multiples.
Wall Street Estimates
GLS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
GLS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
56.1%
=
Gross Profit
12.8B
/
Revenue
22.8B
What is the Gross Margin of Glenmark Life Sciences Ltd?

Based on Glenmark Life Sciences Ltd's most recent financial statements, the company has Gross Margin of 56.1%.

ALPHA SPREAD
Join more than 137,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.